Bolt Biotherapeutics (BOLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has a cash flow conversion efficiency ratio of -0.303x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.73 Million) by net assets ($32.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bolt Biotherapeutics - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Bolt Biotherapeutics carry for a breakdown of total debt and financial obligations.
Bolt Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bolt Biotherapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
0.006x |
|
Finexia Financial Group Ltd
AU:FNX
|
-0.436x |
|
Tempo Inti Media Tbk
JK:TMPO
|
-0.034x |
|
Workspace Group PLC
LSE:WKP
|
0.018x |
|
Medicure Inc
V:MPH
|
-0.030x |
|
Azevedo & Travassos S.A
SA:AZEV3
|
0.479x |
|
Batero Gold Corp
V:BAT
|
-0.003x |
|
Bon Natural Life Ltd
NASDAQ:BON
|
0.076x |
Annual Cash Flow Conversion Efficiency for Bolt Biotherapeutics (2018–2024)
The table below shows the annual cash flow conversion efficiency of Bolt Biotherapeutics from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see BOLT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.20 Million | $-61.29 Million | -1.072x | -73.76% |
| 2023-12-31 | $112.74 Million | $-69.53 Million | -0.617x | -38.25% |
| 2022-12-31 | $171.51 Million | $-76.50 Million | -0.446x | -95.51% |
| 2021-12-31 | $250.12 Million | $-57.07 Million | -0.228x | -150.61% |
| 2020-12-31 | $-104.95 Million | $-47.31 Million | 0.451x | -21.55% |
| 2019-12-31 | $-45.85 Million | $-26.34 Million | 0.575x | -7.20% |
| 2018-12-31 | $-15.94 Million | $-9.87 Million | 0.619x | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more